Physician profile
Christopher Simmons
NPI 1083630081
$1,820.22
in general payments reported to CMS, 2019-2025
22 companies · $63.42 in 2025
The $63.42 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.89 · 2020: $754 · 2021: $622 · 2022: $281 · 2023: $16.40 · 2024: $14.09 · 2025: $63.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $398.48 | 2019-2021 | |
| Amarin Pharma, INC. | $224.69 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $188.10 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.53 | 2019-2022 | |
| Radius Health, INC. | $145.44 | 2020-2022 | |
| Novo Nordisk INC | $131.21 | 2021-2022 | |
| Lilly USA, LLC | $93.29 | 2020-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $75.70 | 2021-2022 | |
| Abbott Laboratories | $68.98 | 2020-2025 | Amplatzer Amulet |
| Glaxosmithkline, LLC. | $49.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.15 | 2019-2020 | |
| Vivus LLC | $39.84 | 2020 | |
| Astellas Pharma US INC | $22.14 | 2021 | |
| Corium, LLC | $21.69 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.21 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $18.86 | 2020 | |
| Daiichi Sankyo INC. | $17.48 | 2020 | |
| Merck Sharp & Dohme LLC | $17.19 | 2020 | |
| Exact Sciences Corporation | $16.40 | 2023 | Cologuard Collection Kit |
| Medtronic Minimed, INC. | $16.22 | 2020 | |
| Sanofi-Aventis U.S. LLC | $15.83 | 2020 | |
| Amgen INC. | $14.09 | 2024 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.